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Abstract
Introduction: Estrogen receptor (ER) b is predicted to play an important role in prevention of breast cancer
development and metastasis. We have shown previously that ERb inhibits hypoxia inducible factor (HIF)-1a
mediated transcription, but the mechanism by which ERb works to exert this effect is not understood.
Methods: Vascular endothelial growth factor (VEGF) was measured in conditioned medium by enzyme-linked
immunosorbent assays. Reverse transcription polymerase chain reaction (RT-PCR), Western blotting,
immunoprecipitation, luciferase assays and chromatin immunoprecipitation (ChIP) assays were used to ascertain the
implication of ERb on HIF-1 function.
Results: In this study, we found that the inhibition of HIF-1 activity by ERb expression was correlated with ERb’s
ability to degrade aryl hydrocarbon receptor nuclear translocator (ARNT) via ubiquitination processes leading to the
reduction of active HIF-1a/ARNT complexes. HIF-1 repression by ERb was rescued by overexpression of ARNT as
examined by hypoxia-responsive element (HRE)-driven luciferase assays. We show further that ERb attenuated the
hypoxic induction of VEGF mRNA by directly decreasing HIF-1a binding to the VEGF gene promoter.
Conclusions: These results show that ERb suppresses HIF-1a-mediated transcription via ARNT down-regulation,
which may account for the tumour suppressive function of ERb.
Introduction
Estrogen plays a key role in the pathogenesis of breast
cancer [1]. The cellular response to estrogen is mediated
by two estrogen receptor (ER) isoforms, ERa and ERb
[2]. ER is the primary target for chemoprevention and
endocrine therapy in breast cancer and provides prog-
nostic and predictive information about tumour
response to endocrine treatment [3]. A series of reports
strongly indicated that estrogens, via ERa, stimulate
proliferation and inhibit apoptosis [4,5], whereas ERb
opposes the proliferative effect of ERa in vitro [6,7].
The alteration of the intracellular ERa/ERb ratio affects
the estrogen-induced cellular response [8]. In addition
to its role in modulating ERa-mediated regulation, ERb
also has distinct functions. Expression of ERb signifi-
cantly reduced cancer cell proliferation and tumour
growth in severe combined immunodeficient mice [9].
ERb inhibited proliferation of colon cancer cells [10]. It
was suggested that the loss of ERb expression may be
one of the events leading to cancer development [11].
Hypoxia regulates a set of cellular functions, such as
increased angiogenesis, energy metabolism, and erythro-
poiesis [12]. The adaptive response to hypoxia is con-
trolled primarily by hypoxia-inducible factors (HIFs),
which are master regulators of hypoxic gene expression
and oxygen homeostasis [13-15]. HIF-1 plays a role in the
physiologic regulation of a number of genes, such as vas-
cular endothelial growth factor (VEGF), erythropoietin,
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[16-18]. HIF-1 functions as a heterodimer, comprised of
an oxygen-labile a-subunit and a stable b-subunit, also
referred to as aryl hydrocarbon receptor nuclear transloca-
tor (ARNT) [15]. The HIF-1a subunit is degraded through
a proteasome pathway under normoxia, whereas ARNT is
constitutively expressed and located in the nucleus. At low
oxygen levels, stabilized HIF-1a translocates to the
nucleus, where the functionally active HIF-1a/ARNT
complex activates the transcription of target genes after
binding to cognate hypoxia-responsive elements (HRE)
[19]. ARNT expression levels constitute important deter-
minants of hypoxia responsiveness [20]. In addition to its
role in the hypoxic pathway, ARNT interacts and func-
tions as a potent coactivator of both ERa-a n dE R b-depen-
dent transcription [21]. The C-terminal domain of ARNT
is essential for the transcriptional enhancement of ER
activity [2]. ARNT is also required for aryl hydrocarbon
receptor (AhR) function in 2,3,7,8-tetrachlorodibenzo-p-
dioxin signalling [22]. Sequestering ARNT, by using a
truncated AhR, blocks the hypoxia and ER signalling path-
ways [23]. The regulation of ARNT is implicated to have a
significant impact on hypoxia and estrogen signalling
pathways.
We recently reported that ERb inhibits HIF-1a-
mediated transcription [24]. However, the mechanism of
ERb on hypoxia-induced transcription is unknown. In
this study, we show that ERb significantly decreases the
hypoxic induction of VEGF mRNA by inhibiting HIF-1-
mediated transcription via ARNT downregulation pro-
viding mechanistic evidence for the anti-angiogenic
effect of ERb.
Materials and methods
Materials
17-b-estradiol (E2) and 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) (Supelco, Bellefonte, PA, USA) were
purchased from Sigma (St. Louis, MO, USA) and dis-
solved in 100% ethanol. ICI182,780 (ICI) was obtained
from ZENECA Pharmaceuticals (Tocris, UK). MG132
(Sigma) was dissolved in dimethyl sulfoxide. All of the
compounds were added to the medium such that the
total solvent concentration was never higher than 0.1%.
An untreated group served as a control. Anti-ERb was
purchased from GeneTex (GTX110607, Irvine, CA,
USA). Anti-ARNT and anti-HIF-1a were obtained from
BD Biosciences (San Jose, CA, USA). Anti-b-actin and
anti-ubiquitin were purchased from Sigma.
Cell culture and hypoxic conditions
Hep3B and Human embryonic kidney 293 (HEK293)
cells were maintained in phenol red-free Dulbecco’s
modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS). MCF-7 and PC3 cells
were maintained in phenol red-free RPMI 1640 medium
supplemented with 10% FBS. Cells were grown at 37°C
in a humidified atmosphere of 95% air/5% CO2 and fed
every two to three days. Before treatment, the cells were
washed with phosphate-buffered saline and cultured in
DMEM/5% charcoal-dextran stripped FBS (CD-FBS) for
two days to eliminate any estrogenic source before treat-
ment. All treatments were done with DMEM/5% CD-
FBS. We used 10 nM E2, unless otherwise noted. For
the hypoxic condition, cells were incubated at a CO2
level of 5% with 1% O2 balanced with N2 using a
hypoxic chamber (Forma, Costa Mesa, CA, USA).
Plasmids
The hERb expression vector was kindly provided by Dr.
Mesut Muyan (University of Rochester Medical School,
USA). The HRE-Luc reporter plasmid contains four
copies of the erythropoietin HRE, the SV40 promoter,
and the luciferase gene. Green fluorescent protein (GFP)
tagged HIF-1a (GFP-HIF-1a) vector was kindly pro-
vided by Dr. Kyu-Won Kim (Seoul National University,
Korea). The plasmid His-tagged ubiquitin (His-Ub) was
c o n s t r u c t e db yi n s e r t i n gas i n g l ec o p yo ft h eU bg e n e
(76 amino acids) into pcDNA3.1/HisC (Invitrogen,
Carlsbad, CA, USA).
Transient transfection and luciferase assay
HEK293 and MCF-7 were transiently transfected with
plasmids by using the polyethylenimine (PEI; Poly-
sciences, Warrington, PA, USA). Luciferase activity was
determined 24 or 48 h after treatment with an AutoLu-
mat LB953 luminometer using the luciferase assay sys-
tem (Promega Corp., Madison, WI, USA) and expressed
as relative light units. The means and standard devia-
tions (SD) of three replicates are shown for the repre-
sentative experiments. All transfection experiments were
repeated three or more times with similar results. PC3
cells were transfected transiently with Lipofectamine
2000 (Invitrogen) and On-Target Plus SMARTpool siR-
NAs (Dharmacon, Lafayette, CO, USA) for ERb Nontar-
geting pools were used as negative controls.
Reverse transcription (RT)-Polymerase chain reation (PCR)
Total RNA was extracted using Trizol reagent (Invitro-
gen) according to the manufacturer’s instruction. RNA
pellets were dissolved in diethylpyrocarbonate-treated
water. To synthesize first strand cDNA, 3 μg total RNA
was incubated at 70°C for five minutes with 0.5 μgo f
random hexamer and deionized water (up to 11 μl). The
reverse transcription reaction was performed using
40 units of M-ML reverse transcriptase (Promega) in 5×
reaction buffer (250 mmol/l Tris-HCl; pH 8.3, 375 mM
KCl, 15 mM MgCl2, 50 mM DTT), RNase inhibitor at
1u n i t / μl, and 1 mM dNTP mixtures at 37°C for
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reaction mixture containing 10× PCR buffer (100 mM
Tris-HCl, pH 8.3, 500 mM KCl, 15 mM MgCl2),
25 units of rTaq polymerase (TakaRa, Shiga, Japan), 4 μl
o f2 . 5m Md N T Pm i x t u r e s ,a n d1 0p m o lo fp r i m e r s
each. The resulting cDNA samples were amplified using
Mastercycler gradient (Eppendorf, Hauppauge, NY, USA).
The primers used were: VEGF sense primer, 5’-
ATGAACTTTCTGCTCTCTGG -3’; anti-sense primer, 5’-
TCATCTCTCCTATGTGCTGGC-3’; b-actin sense pri-
mer, 5’-CCTGACCCTGAAGTACCCCA-3’;a n t i - s e n s ep r i -
mer, 5’-CGTCATGCAGCTCATAGCTC-3’. Quantitative
real-time PCR (qPCR) was used to detect cytochrome p450
(CYP) 1A1. qPCR was performed using iQ™ SYBR Green
Supermix (Bio-Rad, Hercules, CA, USA). The primers used
were: b-actin sense primer, 5’- CAAATGCTTCTAGGCG-
GACTATG-3’; anti-sense primer, 5’- TGCGCAAGT-
TAGGTTTTGTCA -3’; CYP 1A1 sense primer,
5’- TAGACACTGATCTGGCTGCA-3’; anti-sense primer,
5’- GGGAAGGCTCCATCAGCATC-3’;E R b sense pri-
mer, 5’- GTCAGGCATGCGAGTAACAA-3’;a n t i - s e n s e
primer, 5’-GGGAGCCCTCTTTGCTTTTA-3’.Af i n a l
volume was 25 μl, and an iCycler iQ Real-time PCR Detec-
tion System (Bio-Rad) was used for qPCR. The amplifica-
tion data were analyzed by iQ™5 optical system software
version 2.1 and calculated using the ΔΔCT method. The
ΔΔCT method was used to calculate relative mRNA
expression. The relative target gene expression was calcu-
lated using 2
-ΔΔCT,w h e r eΔCT =t a r g e tC T -c o n t r o lC T,
ΔΔCT =ΔCT target - ΔCT calibrator.
VEGF ELISA
After hypoxic exposure, culture medium was removed
and stored at -80°C until assayed. VEGF concentrations
were determined using an ELISA kit (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. Samples from two different experiments
were analyzed in triplicate.
Western blot analysis
Protein extracts were isolated in lysis buffer (150 mM
N a C l ,5 0m MT r i s - H C l( p H8 . 0 ) ,5m ME D T A ,1 %
Nonidet P-40, 0.5% deoxycholate, 1% SDS) with protease
inhibitor cocktail (Sigma) on ice for 1 h and then centri-
fuged for 20 minutes at 13,000 × g. Supernatant was
collected and protein concentrations were measured
using the Bradford method (Bio-Rad). Proteins were dis-
solved in sample buffer and boiled for five minutes prior
to loading onto a polyacrylamide gel. After SDS-PAGE,
proteins were transferred to a polyvinylidene difluoride
membrane, blocked with 5% nonfat dry milk in Tris-
buffered saline containing 0.1% Tween-20 (TBST) for
1 h at room temperature. The membranes were incu-
bated for 2 h at room temperature with antibody. Equal
lane loading was assessed using b-actin monoclonal
antibody (Sigma). After washing with TBST, blots were
incubated with 1:5,000 dilution of the horseradish per-
oxidase conjugated-seconda r ya n t i b o d y( Z y m e d ,S a n
Francisco, CA, USA), and washed again three times with
TBST. The transferred proteins were visualized with an
enhanced chemiluminescence detection kit (Amersham
Pharmacia Biotech, Buckinghamshire, UK).
Immunoprecipitation
Two hundred micrograms of the cell lysates were mixed
with 1 μg of antibody and incubated overnight at 4°C
with constant rotation. To recover immunoprecipitated
complexes, 150 μl of protein A-sepharose, diluted 1:1 in
PBS, were then added to the samples and incubated on
ice for an additional two to four hours with constant
rotation. The beads were pelleted by centrifugation and
the bound proteins were eluted by incubation in 5X
SDS loading buffer for five minutes by boiling. The
eluted proteins were analyzed by immunoblot analysis.
Chromatin immunoprecipitation (ChIP) assay
Hep3B cells exposed to hypoxia as indicated in the fig-
ure legends were cross-linked by adding formaldehyde
to a final concentration of 1% and incubating at 37°C
for 10 minutes. Cells were washed twice with ice-cold
phosphate-buffered saline. Cells were washed sequen-
tially in Buffer 1 (0.25% Triton X-100, 10 mM EDTA,
0.5 mM EGTA, 10 mM HEPES, pH 6.5) and Buffer 2
(200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM
HEPES, pH 6.5). Cells were pelleted at 4°C and resus-
pended in 0.3 ml of cell lysis buffer (50 mM Tris-HCl
pH 8.1, 10 mM EDTA, 1% SDS) containing complete
protease inhibitor mixture (Sigma). Cell lysates were
sonicated to yield DNA fragments ranging in size from
200 to 900 bp. Samples were centrifuged for 15 minutes
at 4°C. Supernatants were diluted 10-fold to a final solu-
tion containing 20 mM Tris-HCl (pH 8.1), 1% Triton
X-100, 2 mM EDTA, 150 mM NaCl, and complete pro-
tease inhibitor mixture. Eluates were then incubated
with 2 μgo fH I F - 1 a antibody (BD Biosciences) over-
night at 4°C followed by the addition of 50 μlo f5 0 %
slurry of protein A or protein G-Sepharose and incu-
bated at 4°C for an additional two hours. Sepharose
beads were pelleted and washed sequentially for 10 min-
utes each in TSE I (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris, pH 8.1, 150 mM NaCl), TSE II
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris, pH 8.1, 500 mM NaCl), and Buffer III (0.25 M
LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA,
10 mM Tris, pH 8.1). Beads were washed another three
times in Tris-EDTA, pH 8.0, and protein-DNA com-
plexes were eluted in 300 μl of elution buffer (1% SDS,
0.1 M NaHCO3). Chemical cross-links were reversed by
Lim et al. Breast Cancer Research 2011, 13:R32
http://breast-cancer-research.com/content/13/2/R32
Page 3 of 12heating the samples overnight at 65°C; the DNA was
separated from protein and used as a template for PCR
reactions. The yield of target region DNA in each sam-
ple after ChIP was analyzed by conventional PCR. The
following primers were used for PCR analysis: VEGF
promoter -1215 to -881 (HRE-containing region), for-
ward 5’- TTGGGCTGATAGAAGCCTTG -3’ and
reverse 5’- TGGCACCAAGTTTGTGGAGC -3’.F o r
qPCR, standard curves were generated by serially dilut-
ing an input chromatin sample. DNA regions were
amplified using the following primers: VEGF promoter
-1077 to -975(HRE-containing region), forward 5’-
CCTCAGTTCCCTGGCAACATCTG-3’ and reverse 5’-
GAAGAATTTGGCACCAAGTTTGT-3’ [GenBank:
AF095785.1].
Statistical analysis
Values shown represent the mean ± SD. Statistical ana-
lysis was performed by Student’s t-test, and a P-value
<0.05 was considered significant.
Results
ERb decreases HIF-1a mediated gene transcription
We have previously reported that overexpression of ERb
suppresses hypoxia-induced endogenous VEGF mRNA
[24]. To determine whether ERb affects hypoxia-induced
VEGF secretion, HEK293 cells were transfected with
vector control or ERb and exposed to hypoxia for 48 h.
VEGF secretion was measured by ELISA. As shown in
Figure 1A, expression of ERb significantly decreased
VEGF secretion under hypoxic condition. To further
characterize the molecular details of ERb inhibition of
hypoxia-induced transcription activation, we studied the
effect of ERb expression on HIF-1a-mediated gene tran-
scription by using an HRE-driven reporter gene.
HEK293 cells were transfected with an HRE-Luc plas-
mid with or without an expression vector for ERb under
hypoxia. As shown in Figure 1B, C, the HRE-driven luci-
ferase reporter was markedly activated by hypoxia,
whereas ERb significantly inhibited this hypoxic activa-
tion in a dose dependent manner. Next, we examined
whether the inhibition was dependent on HIF-1a by
using GFP-HIF-1a, which showed increased stability
enough to carry out HIF-1 functional analyses under
normoxia. The expression of ERb significantly decreased
the transcriptional activity of HIF-1a under normoxia
(Figure 1D). However, the E2 or ER antagonist, ICI, did
not additionally affect this suppression (Figure 1D). This
shows that unoccupied ERb itself serves as a negative
regulator of HIF-1.
HIF-1 suppression by ERb is due to ARNT degradation
Association of HIF-1a with ARNT, forming a heterodi-
meric complex, is required for it to bind to the HRE of
target genes and its subsequent transactivation function
[18]. As adequate levels of ARNT protein are required
for the formation of the active HIF-1 heterodimeric
complex, we determined the effect of ERb on the
expression of ARNT. To our surprise, we observed that
ERb down-regulates the ARNT protein levels in Hep3B
and MCF-7 cells transfected with ERb (Figure 2A). In
addition, ARNT overexpression effectively rescued HIF-
1 repression by ERb (Figure 2B). These results imply
that ERb induced HIF-1 transrepression is attributed to
the down-regulation of ARNT. The involvement of ERb
modulation of ARNT protein level was also confirmed
after knockdown of ERb using RNA interference. As
shown, ARNT protein levels were increased when the
expression of ERb was repressed in PC3 cells. Knock-
down of ERb mRNA by ERb-siRNA were validated by
qPCR (Figure 3A). ERb expression in cell lines used in
this study is shown in Supplementary Figure S1 in Addi-
tional file 1.
To further confirm the decrease in ARNT expression
by ERb, we have examined suppression of AhR activity
which exerts its effect by formation of heterodimer with
ARNT. Dioxin-occupied AhR/ANRT complex is well
known to induce CYP1A1 [25]. As shown, ERb expres-
sion significantly suppressed dioxin induced CYP1A1
expression in MCF-7 cells (Figure 3B). The same effects
were observed in rat hepatocytes (Supplementary Figure
S2 in Additional file 2).
Effects of ERb on ARNT binding with HIF-1a
Our data strongly suggest that ERb decreases HIF-1a
mediated gene transcription through ARNT down-regu-
lation. To further examine the functional consequences
resulting from the degradation of ARNT protein, the
formation of HIF-1a/ARNT complexes was assessed in
HEK293 cells. As shown in Figure 4, GFP-HIF-1a/
ARNT complex levels were significantly decreased by
the overexpression of ERb under normoxia, as deter-
mined by coimmunoprecipitation. In addition, ARNT
overexpression effectively recovered HIF-1a binding to
ARNT (Figure 4), showing that ARNT degradation by
ERb is followed by the reduction of HIF-1a/ARNT
complex formation. In Figure 4, we detected no ARNT
protein upon ERb expression in contrast to the low
levels of ARNT protein in Figure 2A. The difference in
levels of ARNT protein between Figures 2A and 4 is
p r o b a b l yd u et ot h ee f f i c i e n c yo ft e c h n i q u eu s e di n
detection.
ERb degrades ARNT via the ubiquitin proteasome system
The ubiquitin-proteasome pathway is responsible for
many regulatory proteins. To examine the involvement
of the proteasomal pathway in ERb-induced degradation
of ARNT, HEK293 cells were transfected with ERb and
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Figure 1 ERb decreases HIF-1a mediated gene transcription. (a) HEK293 cells in 24-well plates were transfected with hERb (0.2 μg). At 24 h
post-transfection, cells were incubated for 48 h under hypoxic conditions. Culture medium from untransfected HEK293 cells and cells transfected
with hERb plasmids were analyzed using VEGF ELISA kit. Values represent the mean ± S.D. (N = 3). **P <0.01. (b) At 24 h post-transfection of
hERb and HRE-Luc (0.5 μg), cells were incubated for 24 h under normoxic or hypoxic conditions. After incubation, luciferase expression was
determined. Values represent the mean ± S.D. (N = 3). *P <0.05. (c) Cells were transfected with HRE-Luc reporter with or without the expression
vector for 0.1 to 0.4 μg hERb. At 24 h post-transfection, cells were incubated for 24 h under normoxic or hypoxic conditions. After incubation,
luciferase expression was determined. Values represent the mean ± S.D. (N = 3). * P <0.05. (d) Cells were transfected with HRE-Luc reporter and
hHIF-1a (0.2 μg) with or without the expression vector for hERb (0.2 μg). At 24 h post-transfection, cells were left untreated or treated with 10
nM E2 or 1 μM ICI and incubated for 24 h under normoxic conditions. After incubation, luciferase expression was determined. Values represent
the mean ± S.D. (N = 3). * P <0.05. All experiments were repeated at least three times.
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Page 7 of 12treated with or without 10 μM of the proteasome inhibi-
tor, MG132 for 12 h. We analyzed the lysates using
Western blots. As shown in Figure 5A, MG132 signifi-
cantly blocked ARNT degradation by ERb, suggesting
that ERb degrades ARNT via the proteasomal pathway.
Protein ubiquitination is a signal for targeted recogni-
tion and proteolysis by proteasome [26]. To assess ubi-
quitination of ARNT by ERb, cell lysates from HEK293
cells transfected with ERb,A R N T ,a n dH i s - U b iw e r e
immunoprecipitated with anti-ARNT antibody and then
analyzed by Western blot using anti-ubiquitin antibo-
dies. As shown in Figure 5B, ubiqutination of the ARNT
protein was enhanced by ERb expression, indicating that
this process is mediated through the ubiquitin-protea-
some pathway.
ERb decreases the hypoxic induction of VEGF by reducing
the recruitment of HIF-1 to the hypoxia-dependent VEGF
promoter
We have previously reported that ERb decreases VEGF
mRNA in HEK293 cells [24]. To examine the possibility
that ERb modulates the expression of VEGF in other
cells, Hep3B cells were transfected with the expression
vector for ERb and exposed to hypoxia. The hypoxic
induction of VEGF mRNA was significantly blocked by
the overexpression of ERb in Hep3B cells (Figure 6A).
HIF functions by binding to the HREs present in the
promoter of hypoxic genes [27]. To investigate whether
ERb results in reduced HIF-1 recruitment to the VEGF
promoter, we performed ChIP assays on the VEGF pro-
moter in Hep3B cells. As shown in Figure 5B, association
of HIF-1a at the VEGF promoter after ERb overexpres-
sion was significantly decreased compared with that in
hypoxia-treated cells (Figure 6B). This shows that ERb
induced the down-regulation of the HIF-1 target gene
expression resulting from a reduction in the level of HIF-
1 binding to the VEGF promoter.
Discussion
In this study, we sought to determine whether ERb reg-
ulates HIF-1a-mediated transcription by targeting
ARNT. Using a reporter-based assay, we found that ERb
decreased HIF-1a-mediated transcription. Hypoxic
induction of endogenous VEGF was blocked by ERb
expression. This repression is due to ERb-induced
down-regulation of ARNT via ubiquitination processes.
Overexpression of ARNT rescued HIF-1 repression by
ERb. Two important aspects of our study are that it pro-
vides a mechanistic explanation for ERb as a tumour
suppressor and a distinct function for unliganded ERb
in post-translational regulation. The tumour-suppressive
role of ERb in cancer biology currently is being widely
studied [8]. ERb inhibits angiogenesis and growth of
T47D breast cancer xenografts [9]. Coradini et al.
reported that VEGF synthesis under hypoxia was
reduced in ERb-expressing MDA-MB231 breast cancer
cells in contrast to MCF-7 cells containing both the
ERa and ERb isoforms [28]. A very recent study by
Maik et al. showed that ligand-bound ERb impedes
prostate cancer epithelial-mesenchymal transition by
destabilizing HIF-1a and impeding HIF-1 mediated
transcription of VEGF [29]. Our data showed that ERb
suppresses HIF-1 activity and inhibits angiogenesis
related gene expression by targeting ARNT. The detailed
complex regulatory mechanisms of ERb targeting HIF-1
components to proteasome need to be delineated.
ARNT plays a critical role in the transcriptional
response to hypoxia and inactivation of ARNT is suffi-
cient to suppress HIF target gene induction [30,31].
Reducing the cellular levels of ARNT significantly atte-
nuated the transcriptional response of ERb [2]. These
results, along with our data, indicate that ERb-ARNT
crosstalk is an important regulatory constituent
responsible for the inhibitory effects of ERb in hypoxia
response, although the gap between ERb and proteaso-
mal degradation of ARNT still needs to be investi-
gated. Pongratz group has reported the role of ARNT
as a modulator of ERs. C-terminal part of ARNT inter-
acts with the ER ligand binding domain [2]. Since ubi-
quitination by proteins such as carboxyl terminus of
Hsc 70 interacting protein, a regulatory subunit of 26
S proteasome SUG1/TRIP1 and E6-AP ubiquitin ligase
promotes ligand-induced degradation of ERb [32],
ERb-ARNT co-regulator complexes may contain pro-
teins inducing ARNT degradation. Despite the
ARNT ---+
HIF-1D +++
IP: HIF-1Į
+
ERE(Pg)
IB: ARNT
IB: HIF-1Į
- 10 20 20
130
95
Figure 4 Effects of ERb on ARNT binding with HIF-1a.H E K 2 9 3
cells in 100 mm
2 dish were cotransfected with GFP-HIF-1a (10 μg)
and hERb (10 or 20 μg) or ARNT plasmid (10 μg) as indicated. Cell
lysates were immunoprecipitated with anti-HIF-1a antibody and
precipitated proteins were analyzed by immunoblots with anti-HIF-
1a (top) or anti-ARNT antibody (bottom). Shown are representative
results from two to three separate experiments.
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Page 8 of 12extensive study on HIF-1a regulation, little is known
about ARNT regulation. ARNT is present at constitu-
ent levels with a short half life of 4.84 h. There are
other tumour inhibitory substances targeting ARNT
degradation such as curcumin, a major component of
turmeric [33]. Curcumin induces degradation of ARNT
via oxidation and ubiquitination. Further work will
reveal the identity of protein complexes responsible for
ARNT degradation.
The modulation of hypoxic transcription is not con-
fined to the ERb. Nuclear hormone receptors affecting
hypoxic activity are reported by several groups [34-39].
E2 protects against hypoxic/ischemic white matter
damage in the neonatal rat brain [40] and hypoxia-
induced hepatocyte injury through ER-mediated up-
regulation of Bcl-2 [41]. Hypoxia either enhances or
inhibits transcriptional activity of glucocorticoid recep-
tors [42], androgen receptors [43], ERs [24,44-47], and
peroxisome proliferator-activated receptors [48-51]
depending on the experimental systems. Increased glu-
cocorticoid sensitivity after hypoxia exposure has been
observed [52], suggesting that hypoxia may influence the
inflammation process as well. Despite the importance of
understanding the crosstalk between nuclear receptors
and hypoxia-responsive pathways, which will greatly aid
the progress of cancer biology, the mechanism of the
crosstalk is not yet understood. It is possible that com-
mon co-regulator(s) may be involved rather than specific
co-regulators for each nuclear hormone receptor in
hypoxia and nuclear receptor crosstalk. HIF-1 transacti-
vates and down-regulates ERa [45,46], so the co-regula-
tor(s) may contain proteasome activity. Recent reports
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Figure 5 ERb degrades ARNT via the ubiquitin-proteasome system. (a) HEK293 cells were transfected with hERb. At 36 h post-transfection,
cells were treated with 10 μM MG132 for 12 h. The total protein extracts were immunoblotted with ARNT antibody and reprobed with actin
antibody. Values represent the mean ± S.D. (N = 3). * P <0.01. All experiments were repeated at least three times. (b) HEK293 cells in 100Q dish
were transfected with His-Ubi (10 μg) and ARNT plasmid (10 μg) or hERb (10 μg) as indicated. At 36 h post-transfection, cells were treated with
10 μM MG132 for 12 h. Immunoprecipitated ARNT or His-Ubi-conjugated ARNT was detected using anti-ARNT or anti-ubiquitin antibody,
respectively. Arrows indicate the ubiquitinated ARNT protein bands. Molecular weight markers are as shown. The molecular mass of the human
ARNT is 95 kDa. Shown are representative results from two separate experiments.
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Page 9 of 12showed that the carboxy terminus of 70-kDa heat shock
protein-interacting protein, which can degrade ERa,
contains a dual function as an ubiqutin ligase and
tumour suppressor [53].
Another interesting aspect of our result is that the
effect of ERb on hypoxia-mediated response is indepen-
dent of ligand. Unoccupied ERa is known to be asso-
ciated with DNA, even before ligand exposure. ChIP
data showed that unliganded ERa is assembled with
transcription activation complexes for tumour necrosis
factor-a induction [54]. Maynadier et al.r e p o r t e dt h a t
unliganded ERa inhibits cell growth through interaction
with the cyclin-dependent kinase inhibitor p21WAF1
[55]. Lazennec et al. showed that overexpression of ERb
inhibited E2 induced cell proliferation even at low E2
concentration [56] indicating that the effect of is not
dependent on ligand. We and others have reported
increased recruitment of SRC-1 and CBP to ERb by
liganded independent manner by EGF, oncogene ras and
hypoxia [24,57,58]. We envision that unliganded ERb
recruits protein complex containing proteasomal degra-
dation function although we cannot completely preclude
the possibility that in vitro overexpression system have
aberrantly activated ERb.
ȕ-actin
VEGF
ERE
Hypoxia +
- -
-
+
+
V
E
G
F
 
m
R
N
A
,
 
f
o
l
d
c
h
a
n
g
e
0
1
2
3
4
*
VEGF
ERE
hypoxia
-+
-+ +
- -+
-+ +
-
Input 
HIF-1Į
(ChIP Ab)
AB
0
5
10
15
20
25
IgG HIF-1Į
*
ERE
Hypoxia +
- -
-
+
+
R
e
l
a
t
i
v
e
 
f
o
l
d
 
i
n
d
u
c
t
i
o
n
Figure 6 ERb decreases the hypoxic induction of VEGF by reducing the recruitment of HIF-1 to the hypoxia-dependent VEGF
promoter. (a) Hep3B cells in six-well plates were transfected with hERb (2 μg). At 24 h post-transfection, cells were incubated for 24 h under
normoxic or hypoxic conditions. Total RNA from untransfected Hep3B cells and cells transfected with hERb plasmids were analyzed using VEGF-
specific primers, as described in the Materials and Methods. Values represent the mean ± S.D. (N = 3). * P <0.05. All experiments were repeated
at least three times. (b) Hep3B cells were transfected with hERb using the PEI method. At 24 h post-transfection, cells were incubated for 24 h
under hypoxic conditions. After incubation, cells were subjected to ChIP analysis with HIF-1a or control IgG antibody. Shown here are
immunoenriched DNA samples amplified using conventional PCR (top) and quantified results by qPCR (bottom) for an HIF-1a binding site on
the VEGF promoter from three separate experiments.
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In conclusion, our study demonstrated that ERb
degrades ARNT via the ubiquitin-proteasome system
leading to HIF-1 suppression. The ERb/HIF-1a/ARNT
pathway may play an important role in cancer progres-
sion. These findings suggest that HIF-1 suppression by
ERb may represent a potential therapeutic target in
treating patients with ER-associated cancer.
Additional material
Additional file 1: Supplemental Figure S1. Expression level of ERb in
the following cells. MCF7, Hep3B and PC3 cells total protein extracts
were immunoblotted with ARNT, ERb and b-actin antibody.
Additional file 2: Supplemental Figure S2. Effects of ERb expression
on CYP1A1 level. Hepa1c1c7 cells in six-well plates were transfected with
hERb (2 μg) or same amounts of empty vector. At 24 h post-transfection,
cells were treated for 48 h with 1 nM dioxin as indicated. Total protein
extractes were immunoblotted with ARNT and ERb (left panel). Total RNA
were extracted and expression of CYP1A1 was analyzed by qRT-PCR
(right panel). The expression level of 18S rRNA was used for
normalization. The primers used were: mouse Cyp1A1, 5’-
TTCCTGTCCTCCGTTACCTG-3’ and 5’-CCTGTCCTGACAATGCTCAA-3’; 18S
rRNA, 5’-ACCGCAGCTAGGAATAATGGAATA-3’;5 ’-
CTTTCGCTCTGGTCCGTCTT-3.
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